Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended June 30, 2017. The report was signed on July 27, 2017, and incorporates a quarterly report prepared in accordance with Listing Rule 4.7B. The company is a foreign private issuer based in Australia.
Key Financial Metrics
The filing provides a consolidated statement of cash flows but does not contain a statement of comprehensive income; therefore, revenue, profit, and margin data are not available in this document.
- Cash and Cash Equivalents: A$21.9 million at the end of the quarter (June 30, 2017), down from A$23.9 million at the beginning of the quarter.
- Operating Cash Flow: Net cash used in operating activities was A$2.0 million for the quarter and A$6.0 million for the trailing 12 months.
- Investing Cash Flow: Net cash used in investing activities was A$2,000 for the quarter and A$6,000 for the trailing 12 months.
- Financing Cash Flow: Net cash used in financing activities was nil for the quarter and A$46,000 for the trailing 12 months (transaction costs).
- Debt and Liquidity: The company reported no loan facilities or credit standby arrangements drawn or available. There were no borrowings or repayments during the period.
- Government Grants: The company received A$4.8 million in government grants and tax incentives over the trailing 12 months.
Material Changes and Cash Flow Analysis
The primary cash outflows for the quarter were attributed to operating costs, specifically staff costs (A$0.7 million), administration and corporate costs (A$0.3 million), and research and development (A$0.98 million). The decrease in cash and cash equivalents of approximately A$2.0 million during the quarter was primarily driven by operating cash usage, partially offset by interest received (A$35,000) and a favorable exchange rate movement impact of A$22,000. There were no acquisitions or disposals of business entities reported.
Outlook, Risks, and Management Commentary
Estimated Cash Outflows: Management estimates total cash outflows for the next quarter to be A$2.5 million. This includes A$1.2 million for research and development, A$0.7 million for staff costs, and A$0.5 million for administration and corporate costs.
Risks and Contingencies: The filing does not explicitly detail specific risk factors or contingencies beyond the standard disclosure of cash burn and reliance on operating cash flows. The company has no outstanding debt facilities.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name ("Altery Therapeutics Ltd") and the filing registrant name ("Prana Biotechnology Limited").
- Confirm the sustainability of the A$2.5 million quarterly cash burn rate against the current A$21.9 million cash balance.
- Review the nature of the A$4.8 million in government grants received over the last 12 months to assess if they are recurring or one-time items.
- Check for any subsequent equity raises or financing activities not captured in this quarterly cash flow statement.